SOPHiA GENETICS Shares Drop 4.7% After Offering Announcement

SOPHiA GENETICS Announces Underwritten Public Offering

SOPHiA GENETICS SA (NASDAQ:SOPH) disclosed that it intends to conduct an underwritten public offering of its ordinary shares, with the entirety of the shares to be sold directly by the company. The offering is subject to market and other conditions, and the company provided no assurance regarding the timing, completion, or final size and terms of the transaction.

The firm also stated that it will grant the underwriters an option to purchase up to an additional 15 % of the ordinary shares at the public offering price, less the underwriting discount. TD Cowen has been appointed as the lead book‑running manager for the offering.

Following the announcement, SOPHiA GENETICS shares declined 4.7 % in after‑hours trading. The company describes itself as an AI‑native healthcare technology firm focused on expanding access to data‑driven medicine worldwide. Its flagship platform, SOPHiA DDM, leverages artificial intelligence to analyze genomic and multimodal data, delivering insights to hospitals, laboratories, and biopharma institutions.